Argos Therapeutics, a biopharmaceutical company developing and commercializing fully personalized immunotherapies for the treatment of cancer and infectious diseases, has added $17.5 million in Series E financing, bringing the round total to $60 million. The company had previously raised $42.5 million in the round, led by Pharmstandard International, this past August. Current Argos investors and one new investor provided the additional capital.
The Series E funds will be used to support Argos’ ongoing ADAPT Phase 3 clinical trial of ASG-003 for the treatment of metastatic renal cell carcinoma. Among the company’s previous financings was a $50 million Series D investment that valued the company at $186.5 million in 2012.